Hoth Therapeutics (HOTH) Regains Nasdaq Compliance

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement.

On June 18, 2025, the Company received formal notice from the Nasdaq Listing Qualifications Department confirming that Hoth's common stock closed at or above the $1.00 minimum bid price for 10 consecutive trading sessions—from June 4th through June 17- satisfying the requirement under Listing Rule 5550(a)(2). As a result, the compliance matter is officially closed.

"Regaining Nasdaq compliance is a major milestone for Hoth and reflects growing market confidence in our strategy and pipeline," said Robb Knie, CEO of Hoth Therapeutics. "We believe our upcoming catalysts and clinical programs position us for significant value creation in 2025."

With a clean compliance slate and an advancing clinical portfolio, Hoth is now strategically focused on delivering key milestones across multiple therapeutic areas, including inflammatory diseases, oncology, and rare diseases.

You May Also Be Interested In

• Innovative Eyewear to place Lucyd Armor in 150+ big box stores
• InterCure reaches NIS 230M war damage settlement with Israel
• Arbutus Biopharma launches $230M Dutch auction tender offer